Phenelzine	NNP	O
and/or	CC	O
its	PRP$	B
metabolites	NNS	O
also	RB	B
inhibit	VBP	O
at	IN	O
least	JJS	B
two	CD	O
other	JJ	B
enzymes	NNS	O
to	IN	B
a	DT	I
lesser	JJR	O
extent	NN	O
,	,	B
of	IN	I
which	WDT	B
are	VBP	I
alanine	JJ	O
transaminase	NN	O
(	-LRB-	O
ALA	NNP	O
-	HYPH	B
T	NNP	O
)	-RRB-	O
,	,	B
and	CC	I
?-Aminobutyric	JJ	O
acid	NN	O
transaminase	NN	O
(	-LRB-	O
GABA	NNP	O
-	HYPH	B
T	NNP	O
)	-RRB-	O
,	,	B
the	DT	I
latter	NN	O
of	IN	B
which	WDT	I
is	VBZ	B
not	RB	I
caused	VBN	O
by	IN	O
phenelzine	NN	O
itself	PRP	O
,	,	B
but	CC	O
by	IN	O
a	DT	B
phenelzine	NN	O
metabolite	JJ	O
phenylethylidenehydrazine	NN	O
(	-LRB-	O
PEH	NNP	O
)	-RRB-	O
.	.	O

GABA	NNP	O
is	VBZ	B
the	DT	I
major	JJ	B
inhibitory	NN	O
neurotransmitter	NN	O
in	IN	O
the	DT	B
mammalian	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
,	,	B
and	CC	I
is	VBZ	B
very	RB	I
important	JJ	B
for	IN	O
the	DT	B
normal	JJ	O
suppression	NN	O
of	IN	B
anxiety	NN	O
and	CC	B
stress	NN	O
,	,	B
as	RB	O
well	RB	B
as	IN	O
keeping	VBG	O
depression	NN	O
at	IN	O
bay	NN	O
.	.	O

It	PRP	B
is	VBZ	I
thought	VBN	B
that	IN	O
phenelzine	NN	O
's	POS	B
action	NN	O
in	IN	O
increasing	VBG	O
GABA	NNP	O
concentrations	NNS	O
may	MD	B
significantly	RB	O
contribute	VB	O
to	IN	B
its	PRP$	I
antidepressant	NN	O
,	,	B
and	CC	I
especially	RB	O
,	,	B
anxiolytic/antipanic	JJ	O
properties	NNS	O
.	.	O

As	IN	O
for	IN	O
ALA	NNP	O
-	HYPH	B
T	NNP	O
inhibition	NN	O
,	,	B
though	IN	O
the	DT	B
consequences	NNS	O
of	IN	B
disabling	VBG	O
this	DT	B
enzyme	NN	O
are	VBP	B
currently	RB	O
not	RB	B
well	RB	I
understood	VBN	O
,	,	B
there	EX	I
is	VBZ	B
some	DT	I
evidence	NN	B
to	IN	I
suggest	VBP	B
that	IN	O
it	PRP	B
is	VBZ	I
this	DT	B
action	NN	O
of	IN	B
the	DT	I
hydrazines	NNS	O
(	-LRB-	O
including	VBG	O
phenelzine	NN	O
)	-RRB-	O
which	WDT	B
may	MD	I
be	VB	B
responsible	JJ	O
for	IN	O
the	DT	B
occasional	JJ	O
incidence	NN	O
of	IN	B
hepatitis	NN	O
and	CC	B
liver	NN	O
failure	NN	O
.	.	O

